Clinical trial
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
NCT00027300 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00027300 |
|---|---|
| Title | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis |
| Lead sponsor | Biogen, Industry |
| Collaborators | Elan Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | Natalizumab, Placebo |
| Enrollment | 900 |
| Start date | Nov 1, 2001 |
| Primary completion | Nov 1, 2004 |
| Completion | Jan 1, 2005 |
| First posted | Dec 3, 2001 |
| Last update posted | Jan 9, 2017 |
| Countries | Belgium, Canada, Czechia, France, Germany, Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: